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ABSTRACT
Objective To analyse the effects of prevalence and
incidence screening on uptake and detection of cancer in
an ongoing, dynamic programme for colorectal screening
using faecal occult blood testing.
Design Analysis of prevalence and incidence screening.
Setting Three rounds of biennial colorectal screening
using the guaiac faecal occult blood test in east and north
east Scotland, March 2000 to May 2007.
Participants Adults aged 50-69.
Main outcome measures Uptake of screening, test
positivity (percentage of those invited who returned a test
that was positive and triggered an invitation for
colonoscopy), positive predictive value, and stage of
cancer.
Results Of 510990 screening episodes in all three
rounds, 248998 (48.7%) were for prevalence, 163483
(32.0%)were for first incidence, and 98509 (19.3%)were
for second incidence. Uptake of a first invitation for
prevalence screening was 53%and for a second and third
invitation was 15% and 12%. In the cohort invited for the
first round, uptake of prevalence screening rose from55%
in the first round to 63% in the third. The uptake of first
incidence screening on a first invitationwas 54%and on a
second invitation was 86% and on a first invitation for
second incidence screening was 46%. The positivity rate
in prevalence screening was 1.9% and the uptake of
colonoscopy was 87%. The corresponding values for a
first incidence screen were 1.7% and 90% and for a
second incidence screen were 1.1% and 94.5%. The
positive predictive value of a positive faecal occult blood
test result for cancer was 11.0% for prevalence screening,
6.5% for the first incidence screen, and 7.5% for the
second incidence screen. The corresponding values for
the positive predictive value for adenoma were 35.5%,
29.4%, and 26.7%. The proportion of cancers at stage I
dropped from 46.5% for prevalence screening to 41% for
first incidence screening and 35% for second incidence
screening.
Conclusions Repeat invitations to those who do not take
up the offer of screening increases the number of those
who accept, for both prevalence screening and incidence
screening. Although the positive predictive value for both
cancer and adenomas fell between the prevalence screen
and the first incidence screen, they did not fall between
the first and second incidence screens. The deterioration
in cancer stage from prevalence to incidence screening
suggests that some cancers picked up at incidence
screening may have been missed on prevalence
screening, but the stage distribution is still favourable.
These data vindicate the policies of continuing to offer
screening to those who fail to participate and continuing
to offer biennial screening to those who have accepted
previous offers.
INTRODUCTION
In screening programmes where the screening test is
offered at regular intervals, the terms prevalence and
incidence screening are widely used. Prevalence
screening refers to the first time a population is
screened and the term incidence screening is used to
describe subsequent screens.1 Strictly speaking this
nomenclature is incorrect, as no screening test is suffi-
ciently sensitive to detect all prevalent disease in a
population, and disease detected at incidence screen-
ing may have been present at the time of prevalence
screening but was missed by the test. Nevertheless,
study of these distinct screening categories is important
as it provides information that has central implications
for the performance of a programme and in particular
permits estimation of the value of repeated invitations
to participate. In screening for colorectal cancer com-
paratively little is known about the relative effects of
prevalence and incidence screening, as the only infor-
mation that is available from long term screening pro-
grammes comes from population based trials of
screening using the guaiac faecal occult blood test,2-7
where the emphasis was on the effect of the pro-
grammes on disease specific mortality.
As a result of these trials the UK departments of
health commissioned a demonstration pilot to test the
feasibility of introducing a screening programme using
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the guaiac faecal occult blood test into the National
Health Service.8 The pilot was carried out in two
areas, one inEngland and one in Scotland.9 In the Scot-
tish armof this pilot, three biennial rounds of screening
were carried out between 2000 and 2006.10 We exam-
ined the differential effect of prevalence and incidence
screening in the Scottish arm of the pilot.
METHODS
The Scottish arm of the UK demonstration pilot was
carried out inGrampian, Tayside, and Fife, using bien-
nial guaiac faecal occult blood testing (Haemascreen;
Immunostics, Ocean, NJ). Participants with five to six
positive windows on the initial test (strong positive)
were offered colonoscopy, but if one to four windows
were positive (weak positive) participants were asked
to complete a further guaiac faecal occult blood test,
and if subsequent windows were positive colonoscopy
was offered. Minor variations occurred in this algo-
rithm between the three rounds and these are detailed
elsewhere.10
Men andwomenaged 50 to 69 and living in the three
pilot NHS boards were invited for screening. They
were identified by the community health index and
sent a test kit and an invitation to participate by post
from a single screening centre located in Dundee. The
community health index is a unique identifying num-
ber for everyone registered with a general practitioner
in Scotland. The number ismade up of the date of birth
followed by four digits from which sex can be identi-
fied; the precise accuracy of the community health
index in identifying place of residence is unknown,
but fewer than 3% of the invitations were returned
undelivered to the screening centre. Completed tests
were sent back in specially designed foil envelopes to
the unit laboratory for analysis. A specialist nurse con-
tacted those with a positive test result and organised
colonoscopy after informed consent had been
obtained.
Data collectors employed by the screening unit col-
lected information for key performance indicators.
These were analysed by Information Services Scot-
land, a division of NHS National Services Scotland.
All analyses were carried out on anonymised data.
Unlike randomised trials that limited their analyses
to participants recruited in the first round, the second
and third rounds of the demonstration pilot screened
peoplewhowere being invited to prevalence screening
for the first time. In addition, in every round of a
screening programme (other than the first) there is
potential to carry out prevalence screening in people
who failed to respond to a previous invitation. Simi-
larly, it is possible to carry out incidence screening
for the first time in those who had failed to respond to
a previous invitation, and this also holds for secondand
subsequent incidence screens. To add further com-
plexity, it is possible for people to miss incidence
screens but to respond to subsequent invitations—for
example, someone who undergoes prevalence screen-
ing at the first invitation (in the first screening round)
may decline a first incidence screen in the second
round but accept it when it is offered again in the
third round.
Thus in the first round of the demonstration pilot, all
screening episodes were by necessity prevalence
screens from a first invitation. In the second round
there was a mixture of prevalence screens from first
and second invitations and first incidence screens
from a first invitation. By the third round, there was a
complex mix of prevalence screens from first, second,
and third invitations; first incidence screens from first
and second invitations; and second incidence screens
from a first invitation (box).
To assess the effect of prevalence and incidence
screening and hence to gauge the value of continuing
to issue invitations for screening regardless of whether
individuals responded to the invitation, we calculated
the uptake of the different invitations for prevalence
and incidence screening. In addition, for prevalence,
first incidence, and second incidence screening we
determined the uptake of colonoscopy, test positivity,
positive predictive value of the test, and stage of screen
detected cancer.
RESULTS
In all three rounds combined, prevalence screens
totalled 248 998 (169 508 screens in the first round,
38 283 in the second, 41 207 in the third) out of
624 421 invitations. Of these invitations, 409 559
were first invitations, 136 503 second invitations, and
78 359 third invitations.
Similarly, incidence screens totalled261992 (126618
in the second round, 135 374 in the third) of 645362
invitations. Of these invitations, 307235 were first inci-
dence screens on a first invitation, 123 142 were first
incidence screens on a second invitation, and 214 985
were second incidence screens on a first invitation.
Screening episode categories occurring in first three rounds of screening programme
First invitation prevalence—invitees responding to their first invitation to be screened for
the first time
Second invitation prevalence—invitees responding to their second invitation to be
screened for the first time
Third invitation prevalence—invitees responding to their third invitation to be screened for
the first time
First invitation first incidence—invitees responding to their first invitation to be screened
for the second time
Second invitation first incidence—invitees responding to their second invitation to be
screened for the second time—that is, having completed a prevalence screen, they did not
respond to the next invitation but did to the subsequent invitation
First invitation second incidence—invitees responding to their first invitation to be
screened for the third time
Possible categories of screening episodes in the first three rounds:
First round—first invitation prevalence
Second round—first invitation prevalence, second invitation prevalence, and first
invitation first incidence
Third round—any of the six categories above
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Uptake
Uptake of the first invitation to prevalence screeningwas
53%, and this dropped from 55% in the first round to
45% in the second and48% in the third (fig 1); the uptake
of the second invitation for prevalence screening was
15%, and this dropped further to 12% for the third invi-
tation (fig 1). Of the cohort invited to prevalence screen-
ing in the first round, however, uptake of prevalence
screening had risen to 63% by the third round (fig 1).
The uptake of the first incidence screening on a first
invitation was 54%, first incidence screening on the
second invited was 86%, and second incidence screen-
ing on a first invitation was 46% (fig 1).
Uptake of colonoscopy
Uptake of colonoscopy in thosewith a positive guaiac fae-
cal occult blood test result was 87% for prevalence screen-
ing. This rose steadily to 90% for first incidence screening
and to 94.5% for second incidence screening (fig 2).
Positivity
The test positivity (proportion of returned guaiac fae-
cal occult blood test results that were positive for
blood) was 1.9% for prevalence screening, which fell
to 1.7% for first incidence screening and to 1.1% for
second incidence screening (fig 2).
Positive predictive value for cancer and adenoma
The positive predictive value for cancer was 11.0% for
prevalence screening, which fell to 6.5% for first
incidence screeningbut rose slightly to 7.5% for second
incidence screening (fig 2). For adenoma the corre-
sponding positive predictive values were 35.5%,
29.4%, and 26.7%, respectively (fig 2).
Stage at diagnosis
In prevalence screening the proportion of screen
detected cancers diagnosed at stage I (Dukes’ A) was
46.5%, but this fell to 41% for first incidence screening
and to 35% for second incidence screening. However, it
was also found that 6% of cancers diagnosed by preva-
lence screening were stage IV (Dukes’ “D”), but this fell
to 2% for first incidence screening, and by second inci-
dence screeningno cancer diagnosedwas stage IV (fig 3).
DISCUSSION
This study clearly shows that repeated invitations to
screening using faecal occult blood testing have an
effect on uptake. Previously, however, relatively little
was known about the true effect of prevalence and inci-
dence screening. Even in breast cancer screening, stu-
dies that examine prevalence and incidence focus on
screening rounds despite the fact that, with the excep-
tion of the first round, all rounds are a mixture of pre-
valence and incidence screening.11 12 In the UK breast
screening programme, however, it is known that can-
cer detection rates are lower in incidence screens than
in prevalence screens.13
In colorectal cancer some information can be
gleaned from the previous population based trials.
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Fig 1 | (A) Uptake of prevalence screening on first invitation by round, (B) uptake of prevalence screening by invitation, (C)
cumulative uptake of prevalence screening in those invited in first round over all three rounds, and (D) uptake of first and
second incidence screening by invitation
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Reports from a study inNottingham3 do not allow ana-
lysis of uptake by prevalence or incidence screening,
but information is available on positivity, positive pre-
dictive value, and stage at diagnosis. In a Danish
study,4 those who declined an invitation to be screened
were not invited again and hence this study does not
permit detailed scrutiny of the effect of repeated invita-
tions to screening. A Swedish study5 reported on pre-
valence screening, first rescreening, and second
rescreening but only in terms of the three screening
rounds; it did not take into account the mixture of pre-
valence and incidence screening in the second two
rounds and it did not report on the effect of repeated
invitations to prevalence screening. Similarly a French
study,6 in which small geographical areas were allo-
cated to either screening using guaiac faecal occult
blood testing or no screening, reported its results in
terms of screening round rather than by incidence or
prevalence.
Thus to our knowledge our report is the first to separate
out prevalence and incidence screening by individual.
This approach is important as it is the only way of accu-
ratelyestimating theeffect andhence theutilityof repeated
invitations for both prevalence and incidence screening.
In the Scottish demonstrationpilot the uptake of pre-
valence screening was much higher for first invitations
than for subsequent invitations, although over three
rounds repeated invitations increased overall uptake
of prevalence screeningby 8%.Thismay seemmodest,
but it represents 13 561 people who would not have
been screenedhad a decision been taken not to reinvite
thosewhodid not respond to an invitation, aswas done
in the Danish trial.4 For the rolled-out programmes
across the United Kingdom, and in all countries with
screening programmes that rely on repeated
invitations,14 this has substantial implications. The
drop in uptake of prevalence screening on a first invita-
tion observed between the first and subsequent rounds
is probably a function of age, as prevalence screening
in the first round embraced the whole of the 50-69 age
range, unlike the second and third rounds, and it is
known that uptake increases with increasing age.15
The uptakes of the first invitation to first and second
incidence screening were similar to the uptake of the
first invitation to prevalence screening, which is lower
than might be hoped as these were people who had
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already engaged in the screening process. However,
the uptake of the second invitation to first incidence
screening was considerably higher than the first invita-
tion to incidence screening, indicating that those who
decline an offer of incidence screening are likely to
accept further invitations. It is therefore worth while
continuing to offer incidence screening to those who
have defaulted in the past.
The uptake of colonoscopy in those who had a posi-
tive guaiac faecal occult blood test result rose by about
8% between prevalence screening and second inci-
dence screening. This presumably reflects the fact
that those who undergo second incidence screening
represent a particularly compliant group.
The drop in test positivity between prevalence
screening and second incidence screening is not parti-
cularly surprising as the burden of neoplastic disease in
people undergoing incidence screening should be less,
owing to disease detection in previous screens. This is
in keeping with the Nottingham study, which found a
positivity of 2.1% at the first invitation, 1.2% for rescre-
ening within 27 months, and 1.9% with rescreening
after 27 months.3
The positive predictive value for cancer also fol-
lowed the expected pattern of a drop from prevalence
screening to first incidence screening.This is explained
by a reduction in cancer prevalence brought about by
the prevalence screen but without a parallel reduction
in false positive test results. Interestingly, the positive
predictive value did not drop between the first and sec-
ond incidence screens, suggesting that a steady state
may be reached after the prevalence screen. A similar
pattern was seen for positive predictive value for ade-
noma, although this did seem to drop between first and
second incidence screens. It is surprising therefore that
previous studies have not observed these trends. The
positive predictive value for cancer rose between first
screening and rescreening in the Nottingham study3
and significant decreases in the positive predictive
value were not seen between the first and subsequent
rounds in the Danish study4 or the Swedish study.5 In
the French study6 the positive predictive value for can-
cer fell from the first to the second screening round and
then rose to a level thatwas consistently higher than the
first round in the subsequent four rounds. The expla-
nation for the discrepancy between the present study
and previous studies may be related to the mixture of
prevalence and incidence screening in the various
rounds, but this does not explain the findings in the
Nottingham study.
Thedata on stage at diagnosis revealed an interesting
pattern. The proportion of people with early (stage I)
cancer fell progressively from prevalence screening to
first incidence screening. However, the proportion of
people with advanced (stage IV) cancer also fell. This
indicates that the pool of people with unrecognised
metastatic disease is reduced by the prevalence screen,
but this does not hold for the more advanced stages of
localised disease.
Various conclusions can be made from these results.
Firstly, it is clear that repeated invitation for prevalence
screening increases the total number of people who
undergo screening at least once. It also indicates that
repeat invitations for incidence screening have a similar
effect. Even more fundamental is the finding that inci-
dence screening continues to detect important neoplastic
disease. Thus the assumption that repeated screens are
potentially beneficial seems to be vindicated. It could
be argued, however, that the resource required for repeat
invitationsmightbebetter used inotherways—for exam-
ple, to encourage thosewith apositive test result to follow
throughwith colonoscopy.As yet, however, an evidence
base to indicate an appropriate intervention that would
be effective in this respect is lacking.
The patterns of stage at diagnosis for screen detected
cancer raise some particularly interesting issues. It
might have been expected that the prevalence screen
would have detected those people in the population
harbouring advanced (but as yet asymptomatic) dis-
ease in addition to those with early disease, and that
subsequent screens would detect an increasing propor-
tion of early disease.Whereas this assumption seems to
be correct in terms of patients with metastatic disease,
in those with localised disease the proportion with
early cancer actually dropswith progressive screening.
This suggests that at least a proportion of cancers diag-
nosed on incidence screening are not truly incident
cancers but cancers that were missed on previous
screens; this is not surprising given the interval cancer
rate of around 30% that has been previously
reported.10
The results of this study have important implications
for population based screening programmes that test
faeces for blood. They show for the first time that
repeated invitations to both prevalence screening and
incidence screening do pay dividends in terms of
increasing uptake, although this is more pronounced
with incidence screening (that is, in those who have
already engaged with the process). In addition, we
have found that both first and second incidence screen-
ing are associated with significant yields of neoplasia
and that the positive predictive value for cancer does
not drop between first and second incidence screening.
However, the deterioration of stage distribution of
operable screen detected cancers strongly suggests
that at least some cancers detected by incidence screen-
ing had been missed by previous screens. This high-
lights the importance of improving the screening test,
and currently the two strongest candidates are flexible
sigmoidoscopy and faecal immunological testing,
which, unlike the guaiac faecal occult blood test, is spe-
cific for human haemoglobin. A randomised trial
showed faecal immunological testing to bemore sensi-
tive for cancer and adenomas and more acceptable
than the guaiac faecal occult blood test.16 With the
advent of quantitative faecal immunological testing,
where the positivity threshold can be set to take
account of colonoscopy capacity, screening using fae-
cal immunological testing is now a feasible option.
A recently published randomised trial of single flex-
ible sigmoidoscopy showed significant reductions in
cumulative colorectal cancer mortality and incidence17
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and presents an attractive alternative to screening using
aguaiac faecal occult blood test or faecal immunological
test; good evidence suggests that single flexible sigmoi-
doscopy ismore sensitive for cancer andadenomas than
either a single screening using a guaiac faecal occult
blood test or faecal immunological test.17 However,
the flexible sigmoidoscopy trial was effectively carried
out in a volunteer cohort and it is not clear what the
population uptake would be in the United Kingdom
or elsewhere. Independent evidence from the Nether-
lands indicates that uptake of flexible sigmoidoscopy18
is significantly less than that for faecal testing and that
those who are invited for screening find flexible sigmoi-
doscopy more burdensome.19 In addition, although a
single test may have advantages, without repeat invita-
tions an opportunity for increasing uptake is lost.
The future direction of population screening for col-
orectal cancer screening is uncertain, and new more
sensitive and specific tests may become available. In
the meantime, however, it seems that both faecal
immunological testing and flexible sigmoidoscopy
have advantages over guaiac faecal occult blood test-
ing, and indeed faecal immunological testing and flex-
ible sigmoidoscopymay be used effectively in concert.
This study has shown the importance of repeated invi-
tations and highlights the need for careful monitoring
of the effects of prevalence and incidence screening.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
In biennial screening for colorectal cancer using guaiac faecal occult blood testing (gFOBT)
the test positivity rate and the positive predictive value drops between the first round and
subsequent rounds
The differential effect of prevalence and incidence screening on these variables is unknown
The uptake of prevalence and incidence screening has not been studied in this context, so
that the effect of repeated invitations to be screened is unknown
WHAT THIS STUDY ADDS
Uptake of prevalence screening is greatest at the first invitation, but repeat invitations
increase uptake by about 8% over three rounds
Incidence screening detects significant neoplastic disease, and although the positive
predictive value of first incidence screening is less that prevalence screening, it does not drop
with second incidence screening
The stage at diagnosis of operable screen detected cancer deteriorates between prevalence
and first incidence screens, suggesting that incidence screening with gFOBT is detecting
tumours that have been missed on previous screens
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